Market Research Future (MRFR) has published a research report about the global chronic obstructive pulmonary disease (COPD) market that measures huge elevation in this market between 2016 and 2022. This report provides a detailed analysis of market structure with the forecast for next years and provides insights into factors affecting the market growth.
Analyzing the market on the basis of various factors, it evaluates the market with current market size and future potential regarding growth. Profiling various key players in the market, the report discusses their activities and observes competitive developments like joint ventures, mergers and acquisitions, new product developments, strategic alliances, and research and developments (R & D).
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1612
The global chronic obstructive pulmonary disease market has been segmented into medicines, treatments, types, and lastly region. On the basis of medicines, this market has been segmented into antibiotics, bronchodilators, combination inhalers, inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, and theophylline. Antibiotics are useful for fighting bacterial infections. Bronchodilators are medications that open (dilate) the airways (bronchial tubes) of the lung by relaxing bronchial muscles. They allow people with difficulty in breathing to breathe better. A combination inhaler combines two kinds of medicine in one device. Usually, in a combination inhaler, one medicine is corticosteroid while the other is a bronchodilator. Advair Diskus, Breo, Dulera, and Symbicort are some examples of combination inhalers. Some examples of inhaled steroids include Arnuity Ellipta, Flovent, Pulmicort, Qvar, and Symbicort are some examples of inhaled steroids. Oral steroids are the non-narcotic type of powerful prescription medication. Commonly called as a PDE4 inhibitor, phosphodiesterase type 4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4).
Latest Industry News
Pulmonx® Corp. has announced that the US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the USA for treating emphysema patients. 30 JUNE 2018
The FDA’s Pulmonary Allergy Drugs Advisory Committee has voted 16-3 against recommending GlaxoSmithKline’s mepolizumab (Nucala) as an add-on treatment to inhaled corticosteroid-based maintenance treatments that claim to reduce flare-ups in patients with COPD. 25 JUL 2018
Key Players for Global Chronic Obstructive Pulmonary Disease Market
Market Research Future (MRFR) recognizes the following companies as the key players in Chronic Obstructive Pulmonary Disease Market: There are plenty of large and small market players which operate in this market all over the globe.
The key players in global COPD market are Abbott (USA), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland), GSK (UK), Merck (USA), Novartis AG (Switzerland), and Pfizer Inc (USA).
Regional Analysis for Global Chronic Obstructive Pulmonary Disease Market
The regional segmentation of Global Chronic Obstructive Pulmonary Disease Market covers The Americas (North America & South Americas), Europe, Asia Pacific, and Middle East & Africa (MEA). Among the Americas, North America is the bigger market for COPD, than South America due to advanced medical facilities and more investment in this region, the biggest local markets are the United States of America (USA) and Canada. North America is the largest market among all regional markets.
Due to the reasons same as the Americas, Western Europe is the bigger market, than Eastern Europe. Although the market in whole Europe is decent and steady in Western Europe, the cream of Europe market in France, Germany, Italy, Spain, and the United Kingdom (UK). Europe is the second largest market for COPD.
In the Asia Pacific region, the market is growing due to the high density of population and improving medical facilities in some countries of this region. During the forecast period, Asia Pacific is expected to be the fastest growing market for COPD. The biggest markets in the Asia Pacific are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the MEA region, the market is small due to poor or limited infrastructure and less investment in health care. However, due to hookah smoking, the number of people suffering from COPD is sizable. In this region, the biggest markets are Kuwait, Oman, Saudi Arabia, United Arab Emirates (UAE) and Qatar.
Do You Have Specific Requirement? Ask To Our Experts @ https://www.marketresearchfuture.com/enquiry/1612
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Hadapsar, Pune – 411028
Phone: +1 646 845 9312